Details of the Drug Reposition

General Information of This Drug (ID: DMIT8LX)

Drug Name
Fluphenazine   DMIT8LX
Synonyms
FLUPHENAZINE; Triflumethazine; Fluorophenazine; Fluorphenazine; Fluorfenazine; Siqualon; Elinol; 69-23-8; Phthorphenazine; Vespazine; Ftorphenazine; Siqualine; Sevinol; Pacinol; Fluphenazinum; Flufenazina; Prolixin; Flufenazin; Dapotum; Flufenazina [DCIT]; Yespazine; SQ 4918; Fluphenazine [INN:BAN]; Moditen (Tabl or elixir); Fluphenazinum [INN-Latin]; 2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanol; 10-(3-(2-Hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine; UNII-S79426A41Z; HSDB 3334; Dapotum; Prolixine; Fluphenazine hydrochloride; Moditen Hcl; Permitil Concentrate; Prolixin Concentrate; S94; Anatensol (TN); Apo-Fluphenazine; Dapotum (TN); Dapotum D (TN); Dapotum Injektion (TN); Decanoate (TN); Deconoate (TN); Enanthate (TN); Fludecate (TN); Flunanthate (TN); Fluphenazine (INN); Hydrochloride, Fluphenazine; Lyogen (TN); Modecate (TN); Moditen (TN); Moditen Enanthate Injection (TN); Omca (TN); Permitil (TN); Prolixin (TN); Sediten (TN); Selecten (TN); Sevinol (TN); Sinqualone (TN); Trancin (TN)
Therapeutic Class
Antipsychotic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Psychotic disorder DIS4UQOT 6A20-6A25 Approved [1]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Schizophrenia DISSRV2N 6A20 Discontinued in Phase 1 [2]
------------------------------------------------------------------------------------
2 Investigative Indication(s)
Indication Name Indication ID ICD-11 Status REF
Middle East Respiratory Syndrome (MERS) DIS5VPYU 1D64 Investigative [3]
Severe acute respiratory syndrome (SARS) DISYW14W 1D65 Investigative [4]
------------------------------------------------------------------------------------

References

1 Fluphenazine FDA Label
2 Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide
3 Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan;59(1):742-4.
4 Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014 Aug;58(8):4885-93.